Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 5. Rapid correction of low vitamin D status in nursing home residents
Top Ten Searches
etanercept hypertension chf antiphospholipid fibrosis mrsa scid renal cell rickets counterpulsationYour Article Summary
Consistently Stable or Decreased Body Mass Index in Young Adulthood and Longitudinal Changes in Metabolic Syndrome Components: The Coronary Artery Risk Development in Young Adults Study
Circulation, 03/02/07
Lloyd-Jones, Donald M. MD, ScM., et al. – Is BMI the key to halting the the progression of metabolic syndrome risk factors with advancing age?
>Summary: Prospective study of 1358 men and 1321 women ages 18 to 30 years enrolled in from 1985 to 1986, were stratified into groups by baseline BMI and change in BMI
Patients were monitored for changes in metabolic syndrome components over 15 years.
Outcomes: Over 15 years, participants whose BMI remained stable BMI had essentially unchanged levels of metabolic syndrome components, regardless of their baseline BMI, whereas those with an increased BMI had progressively worsening levels. The incidence of metabolic syndrome at year 15 was was lower at 2.2% in the stable BMI group versus 18.8% in the group whose BMI increased. The incidence of developing metabolic syndrome with advancing age can be decreased by maintaining a stable BMI over time
| Previous Article | Next Article |
Today in Atherosclerosis/Lipids...keeping you current
Receive free subspecialty "5-minute updates" via email
Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study)
The American Journal of Cardiology, 06/22/09
Residual cardiovascular risk in treated hypertension and hyperlipidaemia: The PRIME Study
Journal of Human Hypertension, 06/03/09
Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid sub-study
Breast Cancer Research, 06/18/09
Today in Cardiology...keeping you current
Receive free subspecialty "5-minute updates" via email
Catheter ablation vs. amiodarone plus losartan for prevention of atrial fibrillation recurrence in patients with paroxysmal atrial fibrillation
European Journal of Clinical Investigation, 06/01/09
Valsartan for Prevention of Recurrent Atrial Fibrillation
New England Journal of Medicine, 04/16/09
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial
The Lancet - Early Online Publication, 06/09/09
Sponsor
Article Search
Sponsor


See Latest Articles


